XML 29 R22.htm IDEA: XBRL DOCUMENT
v3.24.3

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders | 9 Months Ended
--- | ---
Sep. 30, 2024
Earnings Per Share [Abstract] |
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders | 13. Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the three and nine months ended September 30, 2024 and 2023, respectively (in thousands, except share and per share amounts):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Net loss attributable to Adaptive Biotechnologies Corporation |  | $ | (32,071 | ) |  | $ | (50,300 | ) |  | $ | (125,800 | ) |  | $ | (155,809 | )
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted |  |  | 147,516,398 |  |  |  | 144,704,868 |  |  |  | 146,908,234 |  |  |  | 144,208,940 |
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted |  | $ | (0.22 | ) |  | $ | (0.35 | ) |  | $ | (0.86 | ) |  | $ | (1.08 | )
Given the loss position for all periods presented, basic net loss per share attributable to our common shareholders is the same as diluted net loss per share attributable to our common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the three and nine months ended September 30, 2024 and 2023, respectively, as they had an anti-dilutive effect:
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Stock options outstanding |  |  | 12,520,579 |  |  |  | 13,806,283 |  |  |  | 12,885,829 |  |  |  | 14,054,478 |
Nonvested restricted stock units outstanding |  |  | 10,578,591 |  |  |  | 10,301,308 |  |  |  | 10,697,694 |  |  |  | 9,575,868 |
Maximum nonvested market-based restricted stock units outstanding eligible to be earned |  |  | 3,831,114 |  |  |  | 1,912,674 |  |  |  | 3,385,117 |  |  |  | 1,580,146 |
Total |  |  | 26,930,284 |  |  |  | 26,020,265 |  |  |  | 26,968,640 |  |  |  | 25,210,492 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration